Leadership Team

PathoQuest’s leadership team has significant experience and expertise with in vitro diagnostics and the development, validation and commercialization of metagenomic solutions for the identification of pathogens.

Management team

Jean-Francois Brepson
President & CEO

Colette Côté, Ph.D.
Chief Scientific and Portfolio Officer & US General Manager

Eric Cazergue, MBA
Chief Financial Officer & Head of Human Resources

READ MORE

Jean-François Brepson has over 20 years of leadership experience in the Pharmaceutical Industry. Prior to joining PathoQuest, Mr. Brepson was a Senior Vice-President at IPSEN where he was responsible for leading the global GI-Oncology & Endocrinology Franchise.

Mr. Brepson has an Engineering Degree in Data Management System and a Master’s degree in Foreign Trade. He has also earned “The Leadership & Innovation Certificate” for HEC in Paris and “The Blue Ocean Strategy Certificate” from INSEAD in Fontainebleau-France.

READ MORE

Dr. Côté has nearly 20 years of experience in industry with a focus on applying & expanding the use of NGS in the biosafety testing field. She recently was Head of NGS R&D Testing Services at MilliporeSigma, a well-known stakeholder of the biosafety testing and viral vector manufacturing industry. She started her career as a Senior Scientist at Intronn Inc, and then moved to Innovative Biosensors Inc where she developed and engineered biosensors for rapid biodefense and clinical pathogen detection. Colette received her Ph.D. in Molecular Biology, Cell Biology, and Biochemistry from the Brown University and completed her postdoctoral fellowship in the Genetics and Biochemistry Branch at the NIH. She contributed to various papers, publications, and patents throughout her career.

READ MORE

Prior to joining us, Mr. Cazergue was Finance & Operations Director at Corin France with responsibilities for coordinating the support functions in a post-acquisition and business recovery environment. Before, he was VP of Finance for EMEA APAC at Resmed, a medical device company. Previous to the above, he was CFO at Sanofi Aventis Turkey where he supported the company’s strong business growth and organizational development. He also was also a key contributor to the local merger process of Rhone Poulenc/HMR and between Sanofi/Aventis. Eric Cazergue holds a Master of Business Administration (MBA) from Emlyon Business School (EM Lyon) in Lyon, France, and a Master’s in Finance and Accounting from the University of Lyon.

Sébastien Renouf, Pharm D.
Chief Pharmaceutical Officer, Qualified person

Guillaume Deplaine, Ph.D.
Chief Operating Officer

READ MORE

Dr. Sébastien Renouf has 20 years of experience in Regulatory Affairs, Quality Assurance, and Safety Control for Cell & Gene Therapy. Before joining PathoQuest, Dr. Renouf was Chief Pharmaceutical Officer at CELLforCURE a CDMO specialized in the CART Cells manufacturing and part of the Novartis Group, where he supported the implementation of inspection and marketing authorization accreditation processes. Dr. Renouf has a Pharmacy degree from Paris XI University and is a Therapeutic Biotechnology graduate from Paris VII University and an internship of the Ile-de-France region with an Industrial and Biomedical Pharmacy specialty.

READ MORE

Dr. Guillaume Deplaine has 10 years of experience in the Biotechnology industry. Prior to joining PathoQuest, Dr. Deplaine was the Quality Control and Analytical Development Head at CELLforCURE a CDMO specialized in CART Cells manufacturing, and was part of the Novartis Group. Before, he was Quality Control Head at THERAVECTYS, a company based on lentiviral technology to develop vaccines. Previous to the above, he was Project manager for medical devices in the genetic diagnosis field. Dr. Deplaine is graduated from the University of Pierre et Marie CURIE/Pasteur Institute and holds a Ph.D in Molecular & Cell Biology. He is co-author of several publications and patents.

Management team

Jean-Francois Brepson
President and CEO

READ MORE

Mr. Beaufret is a venture capital partner at Ring, management company of Ring Altitude I,  Ring Mission and Aurinvest Capital 3 , VC funds.  He  is  a member of the Advisory Board at Aurinvest . He is a member of the Board of 6 digital companies.  He also served as advisor at Goldman Sachs in Paris ( 2013-2023), Chief Financial Officer of NBN Co, based in Sydney (Australia-2009-2012) and Chief Financial Officer of Alcatel and Alcatel-Lucent ( 2002-2007)  . He was an Executive in the Ministry of Finance, Deputy Secretary of the international department from 1986 to 1988 and, Deputy Secretary for monetary affairs from 1988 to 1994. He served as General Manager of the French tax administration ( 1997-2000).

He is a graduate of HEC (Paris Business School) and of the ENA (French National School of Public Administration).

Colette Côté, Ph.D.
Chief Scientific and Portfolio Officer & General Manager

READ MORE

Dr. Côté has nearly 20 years of experience in industry with a focus on applying & expanding the use of NGS in the biosafety testing field. She recently was Head of NGS R&D Testing Services at MilliporeSigma, a well-known stakeholder of the biosafety testing and viral vector manufacturing industry. She started her career as a Senior Scientist at Intronn Inc, and then moved to Innovative Biosensors Inc where she developed and engineered biosensors for rapid biodefense and clinical pathogen detection. Colette received her Ph.D. in Molecular Biology, Cell Biology, and Biochemistry from the Brown University and completed her postdoctoral fellowship in the Genetics and Biochemistry Branch at the NIH. She contributed to various papers, publications, and patents throughout her career.

Eric Cazergue, MBA
Chief Financial Officer & Head of Human Resources

READ MORE

Dr. Binder brings more than 30 years of experience in the Life Sciences industry, combining an understanding of therapeutic product development, technologies, and commercialization. He has a world-wide network based on relationships, successful projects and continuous interaction with companies in North America, Europe and Asia. Dr. Binder’s support for corporate development and M&A activities have benefited from both his technical understanding of the field and his visionary view on future needs of the industry.

Sébastien Renouf, Pharm D.
Chief Pharmaceutical Officer, Qualified person

READ MORE

Dr. Sébastien Renouf has 20 years of experience in Regulatory Affairs, Quality Assurance, and Safety Control for Cell & Gene Therapy. Before joining PathoQuest, Dr. Renouf was Chief Pharmaceutical Officer at CELLforCURE a CDMO specialized in the CART Cells manufacturing and part of the Novartis Group, where he supported the implementation of inspection and marketing authorization accreditation processes. Dr. Renouf has a Pharmacy degree from Paris XI University and is a Therapeutic Biotechnology graduate from Paris VII University and an internship of the Ile-de-France region with an Industrial and Biomedical Pharmacy specialty.

Guillaume Deplaine, Ph.D.
COO & Head of Operations

READ MORE

Dr. Guillaume Deplaine has 10 years of experience in the Biotechnology industry. Prior to joining PathoQuest, Dr. Deplaine was the Quality Control and Analytical Development Head at CELLforCURE a CDMO specialized in CART Cells manufacturing, and was part of the Novartis Group. Before, he was Quality Control Head at THERAVECTYS, a company based on lentiviral technology to develop vaccines. Previous to the above, he was Project manager for medical devices in the genetic diagnosis field. Dr. Deplaine is graduated from the University of Pierre et Marie CURIE/Pasteur Institute and holds a Ph.D in Molecular & Cell Biology. He is co-author of several publications and patents.

Stanley Prince
Chief Commercial Officer

READ MORE

Stanley Prince brings 20 years of experience in the vaccine, biologics, and cell/gene therapy fields. He earned his Bachelor of Science degree from Pennsylvania State University and his Master of Business Administration from Alvernia University.   After completing his education Stanley has primarily worked for Contract Research Organizations in increasing leadership roles ranging from the laboratory, project management, and commercial roles. He earned his vaccine, antibody discovery, and GLP experience from Covance. He continued in the antibody therapeutic discovery space working for Immunologix that was the acquired by Intrexon. Stanley had since continued his career in the GMP biosafety area working for BioReliance and Eurofins.  NGS has been part of his biosafety responsibilities for the past 12 years. His expertise spans GMP regulatory biosafety world, GLP technical and commercial areas.

THE FOUNDER

Marc Eloit, Prof.
Founder and Scientific Advisor

Marc Eloit served as a Professor of Virology at the Veterinary School of Maisons-Alfort and held the position of Head of the Pathogen Discovery laboratory at Institut Pasteur Paris until October 2023.

He is a pioneer and consultant in virus discovery and safety of biologicals. He has published a large number of scientific papers in the field of virology. 

He was member of the Virus Safety of Medicinal Products Committee, French Agency of Medicinal Products (1992-2013).

In 2010, he founded PathoQuest, a spin-out of Institut Pasteur dedicated to the comprehensive testing of biologicals using untargeted Next Generation Sequencing (NGS).

Serving as its Chief Scientific Officer (CSO) till 2016, he currently acts as a Scientific Advisor for the company.

The board members

Rainer Metzger, Ph.D., Chairman

READ MORE

Rainer Metzger works as a business professional in the Life Science and Pharmaceutical Industry. He has led numerous co-development, commercialization, M&A, and licensing partnerships. Rainer has been in leading positions in precision medicine, initiating and managing partnerships and services for clinical trials, co-development, and commercialization with QIAGEN, ROCHE, DANAHER, and MEDICOVER establishing and running businesses with pharmaceutical companies. Rainer is acting as a board member for a series of Biotech companies in Europe and the US. He holds a Diploma in natural sciences and genetics and a Ph.D. in Biology and Pharmacology from the University of Heidelberg.

Sascha Alilovic MBA

READ MORE

Mr. Alilovic is a managing partner at SHS Gesellschaft für Beteiligungsmanagement a Tübingen-based investor specializing in healthcare investments. Before this, he held several high management positions as Head of Corporate Finance & Corporate Development at MorphoSys AG, Head of Deal Team and Senior Consultant M&A at Siemens AG, and Senior Director Corporate Finance, M&A at Clairfield SynCap Management. Mr. Alilovic holds a bachelor degree of Science in Computer Science from James Madison University, USA, and an MBA from the European Business School of Deutschland.

Klaus Binder, Ph.D.

READ MORE

Dr. Binder brings more than 30 years of experience in the Life Sciences industry, combining an understanding of therapeutic product development, technologies, and commercialization. He has a world-wide network based on relationships, successful projects and continuous interaction with companies in North America, Europe and Asia. Dr. Binder’s support for corporate development and M&A activities have benefited from both his technical understanding of the field and his visionary view on future needs of the industry.

Daniel Spasic, OPM

READ MORE

Daniel Spasic holds a number of board seats across the life science industry and is a driven life science entrepreneur, strategist and growth advisor with 25 years in senior life science executive roles. He founded TFS HealthSciences (TFS) in 1996, which became a world-leading midsized global clinical Contract Research Organization (CRO). Daniel is the recipient of numerous entrepreneurial achievement awards. In 2010, Daniel received the Swedish National Award as “Man of The Year” by Ernst & Young and in the same year awarded the title “Entrepreneur of The Year” by Founders Alliance and Grant Thornton. His expertise covers biopharma- and healthcare services and technology-enabled services in clinical research. Daniel is acting as a board member for a series of Pharma Service companies in Europe and the US. Daniel is representing S-Growth Holdings LLC; a Boston based family office with investment focus in Pharma Services. He holds a technical degree in chemical engineering and an OPM from Harvard Business School. Daniel is based in Boston, Massachusetts.

Thierry Laugel, Ph.D., MBA

READ MORE

Dr. Thierry Laugel, Ph.D. is a co-Founder and Managing Partner at Kurma Partners since 2009. He was previously Partner at AGF Private Equity, (2006 to 2009) and CDC Innovation (1998 to 2005). Before that, he worked for Flamel Technologies as Project Director for Pharmaceutical R&D (1997-1998) and Fournier Japan, as Coordinator of R&D programmes (1992 – 1996). He has served as Director or Board member in more than 20 companies. Dr. Laugel holds a Pharm.D, a Ph.D. in Pharmacology, and an M.B.A. from INSEAD. 

Jean-Pascal Beaufret

READ MORE

Mr. Beaufret is the Chief Financial Officer of NBN Co. Limited. He also served as a General Manager of Electrobanqueand. He was Executive in the Ministry of Finance, Deputy Secretary of the international department from 1986 to 1988 and, Deputy Secretary for monetary affairs from 1988 to 1994. He served as General Manager of the French tax administration office since 1997. Mr. Beaufret serves as a Member of the Advisory Board at Aurinvest. He has been Vice Chairman at Sequana S.A., since June 27, 2013, and has been its Independent Director since May 21, 2008. He served as Member of the Supervisory Board at Portigon AG since August 1, 2002. He is a graduate of HEC (Paris Business School) and of the ENA (French National School of Public Administration). 

Contact us

U.S.

+1 484 212 9360

466 Devon Park Dr
Wayne, PA 19087
United States

Sign up for our latest news

France

+33 (0)1 70 82 17 90

Biopark -Bâtiment B,
11, rue Watt
75013 Paris, France

How can PathoQuest help?

Name(Required)
This field is for validation purposes and should be left unchanged.

U.S.

+1 484 212 9360

466 Devon Park Dr
Wayne, PA 19087
United States

France

+33 (0)1 70 82 17 90

Biopark -Bâtiment B,
11, rue Watt
75013 Paris, France

How can PathoQuest help?

Name(Required)
This field is for validation purposes and should be left unchanged.

Sign up for our latest news